Endocrine Abstracts

Background: NET-related symptoms such as flushing and diarrhoeas as well as disease related worries reduce quality of life in patients with neuroendocrine tumours (NETs). Peptide receptor radionuclide therapy (PRRT) is an established treatment in NETs and has been shown to prolong survival. However quality of life data post PRRT is lacking.Aim: To evaluate the symptoms prevalence, intensity and their relation to quality of life in patients receiving PRRT...

Introduction: Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin receptor (SSTR) agonists is highly effective and has become an integral part of neuroendocrine tumour (NET) treatment. However, tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. OPS201 (DOTA-JR11) is a very promising next-generation SSTR antagonist selective for SSTR2 (expressed by NETs). This phase 1/2, international, single-...

Introduction: Phaeochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumours with no standardised protocol for treatment. 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is an emerging treatment option for patients with metastatic and/or inoperable PPGL, and with low toxicity. We present our experience with PRRT in advanced PPGL, treated in a ENETS Centre of Excellence.Materials and Methods: 165 patients with...

Introduction: Metastatic phaeochromocytomas (PCC) and paragangliomas (PGL), collectively known as metastatic PPGL (mPPGL), represent uncommon neuroendocrine tumours for which no standardized treatment guidelines exist. The emerging therapeutic modality employing 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) has exhibited favourable tolerability in the management of these patients.Methods: In this...